{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.5","upperLimit":"13.0","value":"11.1"},{"groupId":"OG001","lowerLimit":"7.8","upperLimit":"9.7","value":"8.8"},{"groupId":"OG002","lowerLimit":"5.9","upperLimit":"8.3","value":"7.4"},{"groupId":"OG003","lowerLimit":"6.5","upperLimit":"9.5","value":"8.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"154"},{"groupId":"OG002","value":"85"},{"groupId":"OG003","value":"85"}],"units":"Participants"}],"description":"Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Wild-type KRAS - FOLFOX + Panitumumab"},{"description":"Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.","id":"OG001","title":"Wild-type KRAS - FOLFOX"},{"description":"Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.","id":"OG002","title":"Mutant KRAS - FOLFOX + Panitumumab"},{"description":"Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.","id":"OG003","title":"Mutant KRAS - FOLFOX"}],"paramType":"MEDIAN","populationDescription":"KRAS Evaluable Central Tumor Response Analysis Set: Responders","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}